VANCOUVER, April 15, 2020 /CNW/ - Harvest One Cannabis
Inc. ("Harvest One" or the "Company") (TSX-V: HVT;
OTCQX: HRVOF) is pleased to announce its wholly-owned
subsidiary Satipharm Ltd. ("Satipharm") has expanded its
product offerings to include two new variants of its unique
proprietary CBD Gelpell® product, further enhancing its
product portfolio currently on sale in major retailers and pharmacy
chains throughout the United
Kingdom and Ireland.
Satipharm CBD Advanced Range
The new Satipharm
CBD Advanced range products combine CBD with specifically selected
vitamins in the Company's proprietary Gelpell® capsules.
The Satipharm CBD Advanced range uses the Company's patented
Gelpell® technology to deliver CBD in seamless
microbeads that are clinically proven to increase bioavailability.
The new Advanced range offers two variants, Focus and Active,
designed to address specific consumer's needs.
Active: Satipharm CBD Advanced Active combines CBD
with vitamins A, D, E and K to support general body health and
movement while using the proprietary Gelpell® delivery
technology
Focus: Satipharm CBD Advanced Focus combines CBD
with B vitamins to support mental wellbeing while using the
proprietary Gelpell® delivery technology
"A differentiated product offering is key to building a
successful brand, as we continue to expand our distribution with
major retailers and pharmacy chains throughout the United Kingdom and Ireland," said Andy
Bayfield, Chief Executive Officer of Harvest One. "These
innovative new product variations, Active and Focus offer our
consumers solutions to specific needs, while leveraging our proven
Gelpell® delivery technology."
Satipharm's suite of products now includes its flagship product
10mg CBD Gelpell® capsule, a high strength 50mg CBD
Gelpell® capsule and the CBD Advanced range Focus and
Active variants. It also includes Satipharm's range of Lemon &
Lime and Cinnamon flavoured CBD oils providing a differentiated
market offering to satisfy a larger consumer base.
Satipharm produces a CBD capsule powered by their proprietary
Gelpell® technology. These capsules take a different
approach to other cannabinoid pills currently on the market.
Gelpell® capsules embed the full spectrum hemp extract
CBD in seamless gelatine microspheres. These tiny beads, have
been clinically proven to increase the bioavailability of CBD,
maximising the delivery of CBD to the body. Manufactured in
Switzerland and GMP certified,
every Gelpell® capsule delivers a consistent dose
of cannabinoids.
Satipharm CBD Gelpell capsules have 3.5 times higher
bioavailability compared to standard CBD oils. This unique product
has undergone Stage I and Stage II clinical trials with the results
published in two peer-reviewed international medical journals.
For further details on the clinical trials, please visit our
website;
https://www.harvestone.com/portfolio/satipharm/#clinical-trials
About Harvest One
Harvest One is a global cannabis company that develops and
provides innovative lifestyle and wellness products to consumers
and patients in regulated markets around the world. The Company's
range of lifestyle solutions is designed
to enhance quality of life. Shareholders have significant
exposure to a broad cannabis value chain through its wholly-owned
subsidiaries: United Greeneries, a Licensed
Producer; Satipharm (medical and nutraceutical); and
Dream Water Global, and Delivra (consumer); as well as a
controlling interest in Greenbelt Greenhouse. For more
information, please visit www.harvestone.com.
Cautionary Note Regarding Forward-Looking Statements
Certain statements contained in this press release constitute
forward-looking information. These statements relate to future
events or future performance. The use of any of the words "could",
"intend", "expect", "believe", "will", "projected", "estimated" and
similar expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking
information and are based on the Company's current belief or
assumptions as to the outcome and timing of such future events.
Actual future results may differ materially. The forward-looking
information contained in this press release is made as of the date
hereof, and the Company is not obligated to update or revise any
forward-looking information, whether as a result of new
information, future events or otherwise, except as required by
applicable securities laws. Because of the risks, uncertainties,
and assumptions contained herein, investors should not place undue
reliance on forward-looking information. The foregoing statements
expressly qualify any forward-looking information contained
herein.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE Harvest One Cannabis Inc.